The FDA’s decision means that RiVive stands as the second non-prescription, OTC naloxone nasal spray product that the agency has approved.
FDA commissioner, Robert Califf, said: “We know naloxone is a powerful tool to help quickly reverse the effects of opioids during an overdose.
“Ensuring naloxone is widely available, especially as an approved OTC product, makes a critical tool available to help protect public health.”
